ERBB2 and cancer: It was shown for the first time that emodin treatment impairs the binding of HER2/neu to Hsp90, intracellular redistribution, enhanced ubiquitinylation, and subsequent proteasomal degradation of HER2/neu, which may represent a novel approach for the targeted therapy of HER2/neu-overexpressing cancers [37].